Treatment of metastatic urothelial carcinoma in the United Kingdom, France, Germany, Italy, and Spain
Most patients received platinum-based chemotherapy in first-line, followed by a PD-1/L1 inhibitor. A substantial proportion received best supportive care after second-line. Findings indicate unmet need for the later-line treatment of mUC and provide important context for the emergence of novel therapies.
Authors
- Neil Milloy (ORCID: https://orcid.org/0000-0002-6811-6312)
- Torsten Strunz (ORCID: https://orcid.org/0000-0001-6032-8794)
- Jing Wang-Silvanto
- Ahmet Hasaligil
- Vicki Munro (ORCID: https://orcid.org/0000-0002-3125-5044)
- Maria De Santis (ORCID: https://orcid.org/0000-0002-3196-1336)
- Mia Unsworth
Institutions
- Adelphi Group (United Kingdom) (GB)
- Astellas Pharma (United Kingdom) (GB)
- Medical University of Vienna (AT)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-01-10
- DOI
- https://doi.org/10.1080/14796694.2024.2445498
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- Seagen
- Astellas Pharma
- Astellas Foundation for Research on Metabolic Disorders